

# The scavenging capacity of DMBT1 is impaired by germline deletions

Floris J. Bikker<sup>1</sup> · Caroline End<sup>2</sup> · Antoon J. M. Ligtenberg<sup>1</sup> · Stephanie Blaich<sup>2</sup> · Stefan Lyer<sup>2</sup> · Marcus Renner<sup>2</sup> · Rainer Wittig<sup>2</sup> · Kamran Nazmi<sup>1</sup> · Arie van Nieuw Amerongen<sup>1</sup> · Annemarie Poustka<sup>2</sup> · Enno C.I. Veerman<sup>1</sup> · Jan Mollenhauer<sup>2,3</sup>

Received: 20 December 2016 / Accepted: 27 March 2017 / Published online: 31 March 2017  
© The Author(s) 2017. This article is published with open access at Springerlink.com

**Abstract** The Scavenger Receptor Cysteine-Rich (SRCR) proteins are an archaic group of proteins characterized by the presence of multiple SRCR domains. They are membrane-bound or secreted proteins, which are generally related to host defense systems in animals. Deleted in Malignant Brain Tumors 1 (DMBT1) is a SRCR protein which is secreted in mucosal fluids and involved in host defense by pathogen binding by its SRCR domains. Genetic polymorphism within DMBT1 leads to DMBT1-alleles giving rise to polypeptides with interindividually different numbers of SRCR domains, ranging from 8 SRCR domains (encoded by 6 kb *DMBT1* variant) to 13 SRCR domains (encoded by the 8 kb *DMBT1* variant). In the present study, we have investigated whether reduction from 13 to 8 amino-terminal SRCR domains leads to reduction of bacterial binding. The 6 kb variant bound ~20–45% less bacteria compared to the 8 kb variant. These results support the hypothesis that genetic variation in DMBT1 may influence microbial defense.

**Keywords** SRCR domain · Genetic polymorphism · Pathogen binding · Microbial defense

## Introduction

The Scavenger Receptor Cysteine-Rich (SRCR) proteins are an archaic group of highly conserved proteins in animals (Aruffo et al. 1997; Freeman et al. 1990; Muller et al. 1999; Pahler et al. 1998; Resnick et al. 1994). The SRCR-superfamily is comprised of cell membrane-anchored proteins as well as secretory proteins. SRCR proteins are characterized by the presence of multiple SRCR domains. SRCR domains are approximately 110 amino acids long and are classified into groups A and B based on the number of conserved cysteine residues (six for group A, eight for group B) (Aruffo et al. 1997; Resnick et al. 1994). Generally, SRCR proteins, e.g., the macrophage scavenger receptor, Mac2-binding protein, CD5, CD6, and WC1, have generally been implicated into host defense systems (Aruffo et al. 1997; Aruffo et al. 1991; Elomaa et al. 1998; Freeman et al. 1990; Gough and Gordon 2000; Holmskov et al. 1999; Ligtenberg et al. 2001; Prakobphol et al. 2000; Tino and Wright 1999).

*Deleted in Malignant Brain Tumors 1 (DMBT1)* at chromosome 10q25.3-q26.1 is a member of the group B SRCR superfamily (Holmskov et al. 1997; Holmskov et al. 1999; Ligtenberg et al. 2001; Mollenhauer et al. 1997; Prakobphol et al. 2000). DMBT1 is composed of 13 highly homologous SRCR domains (Aruffo et al. 1997; Hohenester et al. 1999), separated by SRCR-interspersed domains (SIDs), two CUB (C1r/C1s Uegf Bmp1) domains (Bork and Beckmann 1993; Romero et al. 1997), separated by a 14th SRCR domain, and a Zona Pellucida domain (Jovine et al. 2002; Sinowatz et al. 2001). DMBT1 is expressed in saliva (DMBT1<sup>SAG</sup>) and other mucosal fluids along the gastro-intestinal tract, in the lungs (DMBT1<sup>GP340</sup>), and amniotic fluid (Holmskov et al. 1997; Holmskov et al. 1999; Ligtenberg et al. 2004; Mollenhauer et al. 1997; Prakobphol et al. 2000; Reichhardt et al. 2014). In saliva, the concentration of DMBT1<sup>SAG</sup> is approximately 20 µg/ml (Sonesson et al. 2011). DMBT1 plays various roles

✉ Floris J. Bikker  
fbikker@acta.nl

<sup>1</sup> Department of Oral Biochemistry, Academic Centre for Dentistry Amsterdam, University of Amsterdam and VU University Amsterdam, Gustav Mahlerlaan 3004, 1081LA Amsterdam, Netherlands

<sup>2</sup> Division of Molecular Genome Analysis, German Cancer Research Center, Heidelberg, Germany

<sup>3</sup> Molecular Oncology, University of Southern Denmark, Odense, Denmark

in innate immunity, e.g., by activating the MBL-mediated lectin pathway of the complement system (Gunput 2016); it binds to surfactant proteins A and D (Holmskov et al. 1997; Tino and Wright 1999), IgA (Ligtenberg et al. 2004), MUC5B (Thornton et al. 2001), C-type lectin receptors DC-SIGN and Langerin (Boks et al. 2016), influenza virus and HIV (Hartshorn et al. 2003; Stoddard et al. 2007), the dental hard tissue (Bikker et al. 2013), and a wide spectrum of bacteria (Bikker et al. 2004; Bikker et al. 2002; Leito et al. 2008; Madsen et al. 2010). In particular, the SRCR/SID region in DMBT1 appears to play a dominant role in bacterial binding (Bikker et al. 2004; Bikker et al. 2002; Brittan and Nobbs 2015; Kukita et al. 2013).

We have unraveled genetic polymorphism within DMBT1 (Mollenhauer et al. 1999; Mollenhauer et al. 2002b). This results in DMBT1 alleles encoding polypeptides that have different numbers of SRCR domains within the SRCR/SID region, ranging from 8 to 13. This SRCR/SID region does not include the carboxy-terminal SRCR domain, which is located in between the CUB domains. This 14th SRCR domain does not show bacterial-binding activity (Holmskov et al. 1997). Based on analogies to mucins, we postulate that these polymorphisms may lead to a differential efficacy in mucosal protection (Kohlgraf et al. 2003; Mollenhauer et al. 2001; Mollenhauer et al. 2000; Polley et al. 2015).

In the present study, we have selected individuals homozygous for either 8 or 13 SRCR domains and showed a corresponding reduction of the protein size of DMBT1<sup>SAG</sup>. We consistently observed that, compared to wild-type DMBT1 (8 kb, 13 SRCR domains in the SID/SRCR region), the short DMBT1 variant (6 kb, 8 SRCR domains in the SID/SRCR region) displayed 30–45% reduced capacity in binding to bacteria in vitro.

## Materials and methods

### Southern blotting

Genomic DNA from healthy volunteers (ethnic background: Caucasian) was extracted from peripheral blood leukocytes (PBL) according to standard procedures. Collection of blood samples and genetic analyses were approved by the ethics committee of the University of Heidelberg. Twenty-microgram of genomic DNA was digested overnight with the restriction enzyme RsaI (Roche Diagnostics; 10 U/ $\mu$ g DNA), ethanol-precipitated, and resuspended in a total volume of 40  $\mu$ l H<sub>2</sub>O. The digested DNA was separated for 20–22 h on 1.2% (w/v) agarose gels at 45 V. From this point on, everything was exactly done as described previously (Mollenhauer et al. 1999), with the exception that exclusively probe DMBT1/sr1sid2 was used.

### Bacteria

*Streptococcus mutans* (Ingbritt), *Streptococcus gordonii* (HG222) and *Escherichia coli* (F7) were cultured on blood agar plates under anaerobic conditions with 5% CO<sub>2</sub> at 37 °C for 24 h. Subsequently, single colonies were cultured in Todd Hewitt medium and in Luria Broth (Oxoid, Hampshire, United Kingdom) for *S. mutans*, *S. gordonii*, and *E. coli*, respectively, overnight in air/CO<sub>2</sub> (19:1), at 37 °C. Cells were harvested and washed twice in TTC buffer (TBS-Tween-Calcium buffer: TBS, 150 mM NaCl, 10 mM Tris-HCl, pH 7.4; 0.01% (v/v) Tween 20 (poly-sorbate, Merck-Schuchardt, Germany); 1 mM calcium). *Helicobacter pylori* (NCTC 11637) was cultured on selective Dent plates (Oxoid) at 37 °C for 72 h. *H. pylori* was harvested by wiping off the plates and washed twice in NTC buffer (100 mM Sodium acetate, pH 4.2, 0.01% (v/v) Tween 20, supplemented with 1 mM calcium). Bacteria were diluted in buffer to a final OD<sub>700</sub> of 0.5, corresponding with approximately  $5 \times 10^8$  cells/ml.

### Collection of DMBT1<sup>SAG</sup> and determination of relative concentration

Human parotid saliva was collected from healthy donors with a Lashley cup, under stimulation by chewing on sugar-free chewing gum. Collection and use of saliva was approved by the ethics committee of the University of Heidelberg. Twenty-five milliliters of parotid saliva was kept on ice water for 30 min, to promote the formation of a precipitate. This precipitate was collected by centrifugation at 5000xg at 4 °C for 20 min. The resulting pellet was dissolved in 2.5 ml TBS. The pellet was approximately tenfold enriched in DMBT1<sup>SAG</sup> (~200  $\mu$ g/ml), designated as crude DMBT1<sup>SAG</sup>.

For qualitative adhesion assays with DMBT1<sup>SAG</sup>, crude DMBT1<sup>SAG</sup> samples from saliva donors (A and B) were titrated against monoclonal antibody (mAb) DMBT1h12. The antibody recognizes a non-repetitive, non SRCR domain, peptide epitope (amino acid 26–40), which is present within all known DMBT1 variants and locates outside the region that shows germline deletions (Fig. 2a) (Stoddard et al. 2007). High affinity microtiter plates (Greiner-F, Polysorp, Nunc, Kamstrup, Denmark) were coated with crude DMBT1<sup>SAG</sup>, in coating buffer (100 mM sodium carbonate, pH 9.6) for 2 h at 37°C. This incubation and all the following steps were carried out in a volume of 100  $\mu$ l per well at room temperature, and all washes and incubations were carried out in TTC Buffer. Plates were incubated for 1 h with 1:500 mAb DMBT1h12. After washing, the plates were incubated at 37 °C for 1 h with a rabbit anti-mouse IgG-HRP conjugate (dilution 1:2000 in TTC; DAKO A/S, Denmark). Subsequent to three washes with TTC, 100  $\mu$ l TMB-solution (3,3',5,5'-Tetramethyl-benzidine; 125  $\mu$ g/ml in citrate buffer pH 4.5 with 0.05% v/v H<sub>2</sub>O<sub>2</sub>) was added, and after incubation at RT

for 10–15 min, the reaction was stopped by the addition of 50  $\mu$ l 2 M sulphuric acid per well. The absorbance was read at 405 nm on a Dynatech MR7000 plate reader (Billington, UK). The results of the ELISA were used to dilute the different DMBT1<sup>SAG</sup> samples to obtain solutions containing comparable concentrations of the unique DMBT1 epitope, which is not the SRCR-epitope. For the adhesion assay, these equalized DMBT1<sup>SAG</sup> solutions were coated onto microtiterplates.

### Adhesion assays

Bacterial adhesion was examined using a microtiter plate method based on labeling of microorganisms with cell-permeable DNA-binding probes (Bikker et al. 2004; Bikker et al. 2002). Microtiterplates Fluotrac 600 (Greiner, Recklinghausen, Germany) were coated with equal amounts of crude SAG from donors A and B. For this, the samples were dissolved in coating buffer (100 mM sodium carbonate, pH 9.6) and diluted serially. Bovine Serum Albumin (BSA, Sigma-Aldrich, Zwijndrecht, the Netherlands), coated from 1 to 0.01%, was used a control. This experiment was conducted after the adhesion experiments using DMBT1<sup>SAG</sup>. After incubation at 4 °C for 16 h, plates were washed twice with TTC. In case of *H. pylori*, plates were washed with NTC. Subsequently, 100  $\mu$ l of a bacterial suspension ( $5 \times 10^8$  bacteria/ml) were added to each well and incubated for 2 h at 37 °C. Plates were washed three times with TTC, or NTC for *H. pylori*, using a plate washer (Mikrotek EL 403, Winooski, VT). Bound bacteria were detected using 100  $\mu$ l/well of 1 mM SYTO-9 solution (Molecular Probes, Leiden, The Netherlands), a cell-permeable fluorescent DNA-binding probe. Plates were incubated in the dark for 15 min at ambient temperature and washed three times with 0.1% Tween 20. Fluorescence was measured in a fluorescence microtiter plate reader (Fluostar Galaxy, BMG Laboratories, Offenburg, Germany) at 488 nm excitation and 509 nm emission wavelength. The experiments were performed four times, in duplicate.

### SDS-PAGE and western blotting

Samples were incubated at 100 °C for 10 min in sample buffer containing 15 mM Tris-HCl, pH 6.8, 0.5% SDS, 2.5% glycerol, 25 mM dithiothreitol and 0.05% bromophenol blue. SDS-PAGE was conducted on a Pharmacia Phast System (Pharmacia-LKB, Uppsala, Sweden) using 7.5% polyacrylamide gels, according to the manufacturers protocol. The approximate concentration DMBT1<sup>SAG</sup> loaded on SDS-PAGE was 2  $\mu$ g.

Western blotting was performed as described before (Ligtenberg et al. 2001). Nitrocellulose membranes were

incubated with mAb DMBT1h12 antibodies. Bound antibodies were detected with alkaline phosphatase-conjugated to rabbit anti-mouse immunoglobulins (DAKO, Glostrup, Denmark) using 5-bromo-4-chloro-3-indolyl-phosphate (X-P) and nitro blue tetrazolium chloride (NBT) (Boehringer Mannheim, Germany) as substrate.

### Statistical analysis


The mean bacteria binding activity of the 6 and 8 kb variant was compared with Mann-Whitney U tests, using IBM SPSS Statistics for Windows version 20.0 (IBM Corp, Armonk NY, USA). *P* values <0.05 were considered statistical significant.

## Results

### Determination of interindividual polymorphism of DMBT1


Some years ago, we discovered genetic polymorphism within DMBT1 (Mollenhauer et al. 2002a; Mollenhauer et al. 1999; Mollenhauer et al. 2002b) (Fig. 1). This lead us to hypothesize that this polymorphism results in a differential efficacy in mucosal protection. In order to answer this hypothesis, we first screened 200 persons for genetic DMBT1 polymorphism. We found two persons (donors A and C) that were homozygous for a small *DMBT1* variant with 8 SRCR domains in the SID/SRCR region (encoded by the 6 kb *DMBT1* variant). Furthermore, we found two persons (donors B and D) that were homozygous for a large *DMBT1* variant with 13 SRCR domains in the SID/SRCR region (encoded by the 8 kb *DMBT1* variant) (Fig. 1).

Now that DMBT1 polymorphism was found on a genetic level, we wanted to confirm these findings on the polypeptide level. For this, we collected DMBT1<sup>SAG</sup> from the four donors and analyzed protein size by SDS-PAGE and subsequent Western analysis, using mAb DMBT1h12 for immunodetection. In SDS-PAGE DMBT1<sup>SAG</sup> of donors A and C migrated to a position corresponding with an apparent molecular mass of approximately 255 kDa. DMBT1<sup>SAG</sup> of donors B and D migrated in SDS-PAGE to a position corresponding with an apparent molecular mass of approximately 340 kDa. These data agreed with the genetic analysis (Fig. 1), revealing that on the one hand donors A and C express the “short” DMBT1<sup>SAG</sup> of 255 kDa, which putatively contains 8 SRCR domains in the SID/SRCR region. On the other hand, donors B and D express the “long” DMBT1<sup>SAG</sup> isoform, which putatively contains the SID/SRCR region with 13 SRCR domains (Figs. 1 and 2a).



**Fig. 1** DMBT1 polymorphism leads to different length DMBT1 polypeptides. **a** Schematic presentation of the exon-intron structure within the relevant region of *DMBT1* with resulting *RsaI* restriction fragment sizes depicted below. *Gray boxes* denote restriction fragments hybridizing with the probe *DMBT1/sr1sid2*. SR exons coding for scavenger receptor cysteine-rich domains. The hypothetical configurations within the proteins are depicted below. In the carboxy-terminal part of the protein resulting from the deleted allele, it cannot be discerned between a loss of either SR9, SR10, or SR11. Only one of the possibilities is shown. *Pink triangle* signal peptide, *blue box* motif without homology, *SRCR* scavenger receptor cysteine-rich domain, *CUB* C1r/C1s-Uegf-Bmp1 domains, *ZP* zona pellucida domain. *EHD* Eberin-homologous domain, *orange ovals* SRCR interspersed domains (SIDs), *TTT* and *STP* are threonine and serine-threonine-proline-rich domains, respectively. **b** *Top panel* Southern blot analysis of the *DMBT1* genomic configuration in four individuals (A–D)

selected from the panel. Band sizes and exons locating on the restriction fragments are depicted at the *left*. *Bottom panel* Western blot analysis of DMBT1<sup>SAG</sup> protein sizes in the partially purified and concentration-adjusted saliva samples of the four probands. The *arrowhead* denotes the position of the 220-kDa marker band. DMBT1<sup>SAG</sup> was collected from saliva donors that were homozygous for *DMBT1*/8 kb (donors A and C), homozygous for *DMBT1*/6 kb (donors B and D). Crude DMBT1<sup>SAG</sup> from the four donors samples were separated on 7.5% polyacrylamide gels, transferred to nitrocellulose and immunoblotted with mAb DMBT1H12. Lane 1 donor A, lane 2, donor B; lane 3, donor C; lane 4, donor D. DMBT1<sup>SAG</sup> of donors A and C migrated at a position corresponding to an apparent molecular mass of approximately 340 kDa. DMBT1<sup>SAG</sup> of donors B and D runs at a position corresponding to approximately 255 kDa



**Fig. 2** Bacterial binding is dependent on DMBT1 polymorphism. **a** Domain structure of the DMBT1-variant expressed from the large *DMBT1* allele (*DMBT1*/8 kb, 13 SRCR domains within the SRCR/SID region) and the small *DMBT1* allele (*DMBT1*/6 kb, 8 SRCR domains within the SRCR/SID region). *Pink triangle* leader peptide, *blue box* sequence contains unique epitope for mAb DMBT1H12, *red ovals* SRCR domains, *orange ovals*, *SRCR* interspersed domains (SIDs),

*purple boxes* C1r/C1s-Uegf-Bmp1 domains, *green oval* zona pellucida domain, *EHD* Eberin-Homologous Domain. **b** Bacterial binding to DMBT1/8 kb and DMBT1/6 kb (A) was semi-quantified using *S. mutans* (S.m.), *S. gordonii* (S.g.), *E. coli* (E.c.), and *H. pylori* (H.p.). Relative to the wild type DMBT1<sup>SAG</sup>/8 kb we found, on a molecular base, a decrease in bacterial binding to DMBT1<sup>SAG</sup>/6 kb for all bacteria tested. *Error bars* represent the standard error of the mean (SEM),  $P \leq 0.05$

## DMBT1 polymorphism leads to differential bacterial binding

To examine whether this polymorphism affects biological relevant function of DMBT1<sup>SAG</sup>, we compared the bacteria-binding properties of two different genetic variants from donors A (8 kb) and B (6 kb). First, the DMBT1<sup>SAG</sup> content of the various preparations was quantified in ELISA using mAbDMBT1h12. Then, each sample was diluted so that the preparations matched each other in epitope concentration, as was verified by western analysis using mAb DMBT1h12 (Fig. 1b). The solutions subsequently were used to coat microtiter plate wells. Equal coating densities of the different DMBT1 preparations were confirmed by ELISA.

The wells coated with DMBT1<sup>SAG</sup> were incubated with various bacterial species, including *S. mutans*, *S. gordonii*, *E. coli*, and *H. pylori* for 1 h. After washing and addition of the fluorogenic probe, the number of adhering cells was quantified by fluorescence (Fig. 2). The results indicated that wells coated with the short variant DMBT1<sup>SAG</sup> 6 kb bound, on a molar base, significantly less bacteria, than those coated with the long-variant DMBT1<sup>SAG</sup> 8 kb. The relative difference in binding for the bacteria tested were 42.4% (+/−11.7) for *S. mutans* ( $P = 0.016$ ), 32.5% (+/−2.7) for *S. gordonii* ( $P = 0.031$ ), 44.3% (+/−15.5) for *E. coli* ( $P = 0.029$ ) and 35.1% (+/−16.0) for *H. pylori* ( $P = 0.032$ ) (Fig. 2b). No binding was observed on the BSA coated microplates (data not shown).

## Discussion

In this study, we demonstrated that genetic polymorphism, i.e., a reduction of the tandem repeat of the SRCR domains and SIDs of DMBT1, results in a corresponding reduction of the protein size (Fig. 1 and 2a). In a previous study, using an ELISA based adherence assay, was shown that DMBT1<sup>SAG</sup> displays binding to a wide variety of bacteria. Using this assay, we quantified bacterial binding of DMBT1 variants isolated from donors with different genotypes. Based on the assumption that a single SRCR domain contains a single bacterial binding site, located in a putative cleft (Bikker et al. 2004; Bikker et al. 2002; Muller et al. 1999), 8 SRCR within the SRCR/SRCR region domains should theoretically contain 38% less binding capacity than 13 SRCR domains.

We observed that, compared to wild-type DMBT1 (8 kb, 13 SRCR domains in the SID/SRCR region), the short DMBT1 variant (6 kb, 8 SRCR domains in the SID/SRCR region) displayed an about 30–45% reduced capacity to bind Gram-positive and Gram-negative bacteria in vitro. This suggests that genetic polymorphism of DMBT1 impairs its protective functions, as supported by complete inactivation in *DMBT1*-knockout mice (Renner et al. 2007). Genetic polymorphism within *DMBT1* has been described extensively and

appears to be exceptionally high (Mollenhauer et al. 2000; Mollenhauer et al. 1999; Polley et al. 2015). It has also been reported for other SRCR proteins as well, and seems to be an overall characteristic feature of members of the SRCR superfamily. Genetic polymorphism for SRCR proteins has been reported, e.g., for human CD5 (Padilla et al. 2000), human CD163 sponge Aggregation Receptor (Muller et al. 1999; Pancer 2000), and sheep T19 (Walker et al. 1994). Genetic polymorphism of *DMBT1* was suggested to be linked to functionality, i.e., bacterial binding and hydroxyapatite binding of the polypeptide of DMBT1<sup>SAG</sup> (Bikker et al. 2013; Bikker et al. 2002). Copy number variants that bound strongly to *S. mutans* and less to hydroxyapatite seemed to be increased in agricultural populations compared to hunter-gatherer populations and ancient hominins (Polley et al. 2015). As *S. mutans* is the causative agent in dental caries; it was speculated that some kind of selection for caries resistance had occurred in agricultural populations. We show that deletion of the SRCR domains not only affects binding to *S. mutans*, but also to other bacteria. Selective pressure from other bacterial infections, which occur more frequently in agricultural populations, may have favored the selection of strong binding copy number variants.

It has to be noted that in this study crude preparations of DMBT1<sup>SAG</sup> were used for bacterial adhesion analysis.

Although, it cannot be excluded that a variety of proteins such as amylase, proline rich proteins, and s-IgA may have coprecipitated with DMBT1<sup>SAG</sup>; it appears that crude DMBT1<sup>SAG</sup> shows representative bacteria binding characteristics. In line with earlier studies with purified DMBT1<sup>SAG</sup> and recombinant DMBT1, crude DMBT1<sup>SAG</sup> preparations show comparable bacteria binding characteristics (Bikker et al. 2004; Bikker et al. 2002; End et al. 2009; End et al. 2005; Leito et al. 2008; Ligtenberg et al. 2004; Ligtenberg et al. 2001). And, as DMBT1<sup>SAG</sup> is obtained directly from the parotid gland, the presence of bacteria-binding salivary mucins (MUC7) can be excluded (Veerman et al. 1996).

The present data suggest that the SRCR/SID region defines a complex multi-allele system that represents a possible basis for the variability in human susceptibility to infection as suggested in earlier papers (Mollenhauer et al. 2002a; von Deimling et al. 2000).

**Acknowledgements** This work was supported by the European Molecular Biology Organization (EMBO), grant ASTF 115-02, the Netherlands Organization for Scientific Research (NWO), grant ER 90-184, the Deutsche Krebshilfe, grant no. 1835-Mo I, and the Wilhelm Sander-Stiftung, grant no. 99.018.2.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

## References

- Aruffo A, Bowen MA, Patel DD, Haynes BF, Starling GC, Gebe JA, Bajorath J (1997) CD6-ligand interactions: a paradigm for SRCR domain function? *Immunol Today* 18:498–504
- Aruffo A, Melnick MB, Linsley PS, Seed B (1991) The lymphocyte glycoprotein CD6 contains a repeated domain structure characteristic of a new family of cell surface and secreted proteins. *J Exp Med* 174:949–952
- Bikker FJ, Cukkemane N, Nazmi K, Veerman EC (2013) Identification of the hydroxyapatite-binding domain of salivary agglutinin. *Eur J Oral Sci* 121:7–12
- Bikker FJ, Ligtenberg AJ, End C, Renner M, Blaich S, Lyer S, Wittig R, van't Hof W, Veerman EC, Nazmi K, de Blicke-Hogervorst JM, Kioschis P, Nieuw Amerongen AV, Poustka A, Mollenhauer J (2004) Bacteria binding by DMBT1/SAG/gp-340 is confined to the VEVLXXXXW motif in its scavenger receptor cysteine-rich domains. *J Biol Chem* 279:47699–47703
- Bikker FJ, Ligtenberg AJ, Nazmi K, Veerman EC, van't Hof W, Bolscher JG, Poustka A, Nieuw Amerongen AV, Mollenhauer J (2002) Identification of the bacteria-binding peptide domain on salivary agglutinin (gp-340/DMBT1), a member of the scavenger receptor cysteine-rich superfamily. *J Biol Chem* 277:32109–32115
- Boks MA, Gunput ST, Kosten I, Gibbs S, van Vliet SJ, Ligtenberg AJ, van Kooyk Y (2016) The human glycoprotein salivary agglutinin inhibits the interaction of DC-SIGN and langerin with oral microorganisms. *J Innate Immun* 8:350–361
- Bork P, Beckmann G (1993) The CUB domain. A widespread module in developmentally regulated proteins. *J Mol Biol* 231:539–545
- Brittan JL, Nobbs AH (2015) Group B *Streptococcus* pili mediate adherence to salivary glycoproteins. *Microbes Infect* 17:360–368
- Elomaa O, Sankala M, Pikkarainen T, Bergmann U, Tuuttila A, Raatikainen-Ahokas A, Sariola H, Tryggvason K (1998) Structure of the human macrophage MARCO receptor and characterization of its bacteria-binding region. *J Biol Chem* 273:4530–4538
- End C, Bikker F, Renner M, Bergmann G, Lyer S, Blaich S, Hudler M, Helmke B, Gassler N, Autschbach F, Ligtenberg AJ, Benner A, Holmskov U, Schirmacher P, Nieuw Amerongen AV, Rosenstiel P, Sina C, Franke A, Hafner M, Kioschis P, Schreiber S, Poustka A, Mollenhauer J (2009) DMBT1 functions as pattern-recognition molecule for poly-sulfated and poly-phosphorylated ligands. *Eur J Immunol* 39:833–842
- End C, Lyer S, Renner M, Stahl C, Ditzler J, Holloschi A, Kuhn HM, Flammann HT, Poustka A, Hafner M, Mollenhauer J, Kioschis P (2005) Generation of a vector system facilitating cloning of DMBT1 variants and recombinant expression of functional full-length DMBT1. *Protein Expr Purif* 41:275–286
- Freeman M, Ashkenas J, Rees DJ, Kingsley DM, Copeland NG, Jenkins NA, Krieger M (1990) An ancient, highly conserved family of cysteine-rich protein domains revealed by cloning type I and type II murine macrophage scavenger receptors. *Proc Natl Acad Sci U S A* 87:8810–8814
- Gough PJ, Gordon S (2000) The role of scavenger receptors in the innate immune system. *Microbes Infect* 2:305–311
- Gunput ST, Wouters D, Nazmi K, Cukkemane N, Brouwer M, Veerman EC, Ligtenberg AJ (2016) Salivary agglutinin is the major component in human saliva that modulates the lectin pathway of the complement system. *Innate Immun* 22:257–65
- Hartshorn KL, White MR, Mogues T, Ligtenberg T, Crouch E, Holmskov U (2003) Lung and salivary scavenger receptor glycoprotein-340 contribute to the host defense against influenza A viruses. *Am J Physiol Lung Cell Mol Physiol* 285:L1066–L1076
- Hohenester E, Sasaki T, Timpl R (1999) Crystal structure of a scavenger receptor cysteine-rich domain sheds light on an ancient superfamily. *Nat Struct Biol* 6:228–232
- Holmskov U, Lawson P, Teisner B, Tornøe I, Willis AC, Morgan C, Koch C, Reid KB (1997) Isolation and characterization of a new member of the scavenger receptor superfamily, glycoprotein-340 (gp-340), as a lung surfactant protein-D binding molecule. *J Biol Chem* 272:13743–13749
- Holmskov U, Mollenhauer J, Madsen J, Vitved L, Gronlund J, Tornøe I, Kliem A, Reid KB, Poustka A, Skjodt K (1999) Cloning of gp-340, a putative opsonin receptor for lung surfactant protein D. *Proc Natl Acad Sci U S A* 96:10794–10799
- Jovine L, Qi H, Williams Z, Litscher E, Wassarman PM (2002) The ZP domain is a conserved module for polymerization of extracellular proteins. *Nat Cell Biol* 4:457–461
- Kohlgraf KG, Gawron AJ, Higashi M, Meza JL, Burdick MD, Kitajima S, Kelly DL, Caffrey TC, Hollingsworth MA (2003) Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line. *Cancer Res* 63:5011–5020
- Kukita K, Kawada-Matsuo M, Oho T, Nagatomo M, Oogai Y, Hashimoto M, Suda Y, Tanaka T, Komatsuzawa H (2013) *Staphylococcus aureus* SasA is responsible for binding to the salivary agglutinin gp340, derived from human saliva. *Infect Immun* 81:1870–1879
- Leito JT, Ligtenberg AJ, Nazmi K, de Blicke-Hogervorst JM, Veerman EC, Nieuw Amerongen AV (2008) A common binding motif for various bacteria of the bacteria-binding peptide SRCRP2 of DMBT1/gp-340/salivary agglutinin. *Biol Chem* 389:1193–1200
- Ligtenberg AJ, Bikker FJ, De Blicke-Hogervorst JM, Veerman EC, Nieuw Amerongen AV (2004) Binding of salivary agglutinin to IgA. *Biochem J* 383:159–164
- Ligtenberg TJ, Bikker FJ, Groenink J, Tornøe I, Leth-Larsen R, Veerman EC, Nieuw Amerongen AV, Holmskov U (2001) Human salivary agglutinin binds to lung surfactant protein-D and is identical with scavenger receptor protein gp-340. *Biochem J* 359:243–248
- Madsen J, Mollenhauer J, Holmskov U (2010) Review: Gp-340/DMBT1 in mucosal innate immunity. *Innate Immun* 16:160–167
- Mollenhauer J, Helmke B, Muller H, Kollender G, Lyer S, Diedrichs L, Holmskov U, Ligtenberg T, Herberth S, Krebs I, Wiemann S, Madsen J, Bikker F, Schmitt L, Otto HF, Poustka A (2002a) Sequential changes of the DMBT1 expression and location in normal lung tissue and lung carcinomas. *Genes Chromosomes Cancer* 35:164–169
- Mollenhauer J, Herberth S, Helmke B, Kollender G, Krebs I, Madsen J, Holmskov U, Sorger K, Schmitt L, Wiemann S, Otto HF, Grone HJ, Poustka A (2001) Deleted in malignant brain tumors 1 is a versatile mucin-like molecule likely to play a differential role in digestive tract cancer. *Cancer Res* 61:8880–8886
- Mollenhauer J, Herberth S, Holmskov U, Tolnay M, Krebs I, Merlo A, Schroder HD, Maier D, Breitling F, Wiemann S, Grone HJ, Poustka A (2000) DMBT1 encodes a protein involved in the immune defense and in epithelial differentiation and is highly unstable in cancer. *Cancer Res* 60:1704–1710
- Mollenhauer J, Holmskov U, Wiemann S, Krebs I, Herberth S, Madsen J, Kioschis P, Coy JF, Poustka A (1999) The genomic structure of the DMBT1 gene: evidence for a region with susceptibility to genomic instability. *Oncogene* 18:6233–6240
- Mollenhauer J, Muller H, Kollender G, Lyer S, Diedrichs L, Helmke B, Holmskov U, Ligtenberg T, Herberth S, Krebs I, Madsen J, Bikker F, Schmitt L, Wiemann S, Scheurlen W, Otto HF, von Deimling A, Poustka A (2002b) The SRCR/SID region of DMBT1 defines a complex multi-allele system representing the major basis for its variability in cancer. *Genes Chromosomes Cancer* 35:242–255
- Mollenhauer J, Wiemann S, Scheurlen W, Korn B, Hayashi Y, Wilgenbus KK, von Deimling A, Poustka A (1997) DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours. *Nat Genet* 17:32–39
- Muller WE, Koziol C, Muller IM, Wiens M (1999) Towards an understanding of the molecular basis of immune responses in sponges: the

- marine demosponge *Geodia cydonium* as a model. *Microsc Res Tech* 44:219–236
- Padilla O, Calvo J, Vila JM, Arman M, Gimferrer I, Places L, Arias MT, Pujana MA, Vives J, Lozano F (2000) Genomic organization of the human CD5 gene. *Immunogenetics* 51:993–1001
- Pahler S, Blumbach B, Muller I, Muller WE (1998) Putative multiadhesive protein from the marine sponge *Geodia cydonium*: cloning of the cDNA encoding a fibronectin-, an SRCR-, and a complement control protein module. *J Exp Zool* 282:332–343
- Pancer Z (2000) Dynamic expression of multiple scavenger receptor cysteine-rich genes in coelomocytes of the purple sea urchin. *Proc Natl Acad Sci U S A* 97:13156–13161
- Polley S, Louzada S, Forni D, Sironi M, Balaskas T, Hains DS, Yang F, Hollox EJ (2015) Evolution of the rapidly mutating human salivary agglutinin gene (DMBT1) and population subsistence strategy. *Proc Natl Acad Sci U S A* 112:5105–5110
- Prakobphol A, Xu F, Hoang VM, Larsson T, Bergstrom J, Johansson I, Frangmyr L, Holmskov U, Leffler H, Nilsson C, Boren T, Wright JR, Stromberg N, Fisher SJ (2000) Salivary agglutinin, which binds *Streptococcus mutans* and *Helicobacter pylori*, is the lung scavenger receptor cysteine-rich protein gp-340. *J Biol Chem* 275:39860–39866
- Reichhardt MP, Jarva H, de Been M, Rodriguez JM, Jimenez Quintana E, Loimaranta V, de Vos WM, Meri S (2014) The salivary scavenger and agglutinin in early life: diverse roles in amniotic fluid and in the infant intestine. *J Immunol* 193:5240–5248
- Renner M, Bergmann G, Krebs I, End C, Lyer S, Hilberg F, Helmke B, Gassler N, Autschbach F, Bikker F, Strobel-Freidekind O, Gronert-Sum S, Benner A, Blaich S, Wittig R, Hudler M, Ligtenberg AJ, Madsen J, Holmskov U, Annese V, Latiano A, Schirmacher P, Amerongen AV, D'Amato M, Kioschis P, Hafner M, Poustka A, Mollenhauer J (2007) DMBT1 confers mucosal protection in vivo and a deletion variant is associated with Crohn's disease. *Gastroenterology* 133:1499–1509
- Resnick D, Pearson A, Krieger M (1994) The SRCR superfamily: a family reminiscent of the Ig superfamily. *Trends Biochem Sci* 19:5–8
- Romero A, Romao MJ, Varela PF, Kolln I, Dias JM, Carvalho AL, Sanz L, Topfer-Petersen E, Calvete JJ (1997) The crystal structures of two spermadhesins reveal the CUB domain fold. *Nat Struct Biol* 4:783–788
- Sinowatz F, Kolle S, Topfer-Petersen E (2001) Biosynthesis and expression of zona pellucida glycoproteins in mammals. *Cells Tissues Organs* 168:24–35
- Sonesson M, Ericson D, Kinnby B, Wickstrom C (2011) Glycoprotein 340 and sialic acid in minor-gland and whole saliva of children, adolescents, and adults. *Eur J Oral Sci* 119:435–440
- Stoddard E, Cannon G, Ni H, Kariko K, Capodici J, Malamud D, Weissman D (2007) gp340 expressed on human genital epithelia binds HIV-1 envelope protein and facilitates viral transmission. *J Immunol* 179:3126–3132
- Thornton DJ, Davies JR, Kirkham S, Gautrey A, Khan N, Richardson PS, Sheehan JK (2001) Identification of a nonmucin glycoprotein (gp-340) from a purified respiratory mucin preparation: evidence for an association involving the MUC5B mucin. *Glycobiology* 11:969–977
- Tino MJ, Wright JR (1999) Glycoprotein-340 binds surfactant protein-A (SP-A) and stimulates alveolar macrophage migration in an SP-A-independent manner. *Am J Respir Cell Mol Biol* 20:759–768
- Veerman EC, van den Keybus PA, Vissink A, Nieuw Amerongen AV (1996) Human glandular salivas: their separate collection and analysis. *Eur J Oral Sci* 104:346–352
- von Deimling A, Fimmers R, Schmidt MC, Bender B, Fassbender F, Nagel J, Jahnke R, Kaskel P, Duerr EM, Koopmann J, Maintz D, Steinbeck S, Wick W, Platten M, Muller DJ, Przkora R, Waha A, Blumcke B, Wellenreuther R, Meyer-Puttitz B, Schmidt O, Mollenhauer J, Poustka A, Stangl AP, Lenartz D, von Ammon K (2000) Comprehensive allelotyping and genetic analysis of 466 human nervous system tumors. *J Neuropathol Exp Neurol* 59:544–558
- Walker ID, Glew MD, O'Keeffe MA, Metcalfe SA, Clevers HC, Wijngaard PL, Adams TE, Hein WR (1994) A novel multi-gene family of sheep gamma delta T cells. *Immunology* 83:517–523